期刊文献+

西妥昔单抗联合放疗对鼻咽癌细胞凋亡影响的研究 被引量:4

Enhancement of radiosensitivity by cetuximab in nasopharyngeal carcinoma
原文传递
导出
摘要 目的:西妥昔单抗(C225)对鼻咽癌细胞放疗增敏作用及其相关机制的研究。方法:通过免疫细胞化学法测得EG-FR在鼻咽癌CNE-2Z细胞株中的表达水平,MTT法测出西妥昔单抗在体外细胞实验中的工作浓度,克隆形成实验测定不同处理组的Do、SER值。将细胞分为对照组(N)、单纯照射组(R)、单纯用药组(C)和放疗联合使用西妥昔单抗组(RC)4组,应用流式细胞技术(Annexin V/PI标记)检测西妥昔单抗在体外对鼻咽癌细胞凋亡的影响。结果:免疫细胞化学法检测鼻咽癌CNE-2Z细胞株EGFR呈高表达水平。克隆形成实验测出放疗联合西妥昔单抗组Do低于单纯照射组,SER为1.581 1±0.035 7,P<0.05。放疗联合用药组的细胞凋亡率为(31.9±0.98)%,单纯放疗组的细胞凋亡率为(13.1±0.60)%,单纯用药组的细胞凋亡率为(6.4±0.95)%,对照组的细胞凋亡率为(2.5±0.51)%,放疗联合用药组的细胞凋亡率明显高于单纯处理组和对照组,P<0.05。结论:西妥昔单抗增加了鼻咽癌细胞对放疗的敏感性,其机制可能与其诱导细胞凋亡有关。 OBJECTIVE: To investigate the mechanism of enhancement of radiosensitivity by Cetuximab in nasopharyngeal carcinoma. METHODS: The expression of EGFR of nasopharyngeal carcinoma CNE-2Z cell line was tested by immunohistochemistry (IHC) and the working concentration of Cetuximab in vitro was detected by MTT colorimetry. Four groups were as follows: No treatment group(N),Radiation alone group (R),Cetuximab alone group (C),Cetuximab after Radiation group (RC). The working concentration were used to the four groups. The apoptosis-inducing effect of Cetuximab in vitro was detected via flow cytometry (Annexin V/PI labeled). RESULTS: The expression of EGFR of CNE-2Z cell line was positive by IHC. The Do in Cetuximab and radiation group was lower than that in the radiation alone group. The SER of CR group was 1. 581 li0. 035 7 (P〈0. 05). The apoptosis rate of radiotherapy and cetuximab group was (31.9±0. 98)% ,the radiation alone group was (13.1 ± 0. 60) %, the cetuximab alone group was (6.4±0.95) % and no treatment group was (2.5 ±0. 51) %. FCM showed more prominent apoptosis induced by cetuximab combined with radiation compared to cetuximab or radiation alone groups (P〈0.05). CONCLUSION:Cetuximab can enhance the radiosensitivity of the CNE-2Z cell, which may be asso- ciated with apoptosis induction.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第14期1053-1056,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 广东省科技计划项目(2007B031516001)
关键词 鼻咽肿瘤 放射疗法 鼻咽肿瘤 药物疗法 抗体 单克隆 细胞凋亡 nasopharyngeal neoplasms/radiotherapy nasopharyngeal neoplasms/drug therapy antibodies, mono- clonal apoptosis
  • 相关文献

参考文献11

  • 1钱家鸣.食管癌[M]//叶任高,陆再英.内科学.6版.北京:人民卫生出版社,2004:374-377.
  • 2李先明,李子煌,吴超权,胡岳然,杨东,吴冬,闫茂生,徐钢.鼻咽癌根治性放射治疗的预后分析[J].中华肿瘤防治杂志,2009,16(15):1173-1177. 被引量:23
  • 3Choong NW,Cohen EE, Epidermal growth factor receptor di-rected therapy in head and neck cancer[J]. Crit Rev Oncol He-matol,2006,57(1):25-43.
  • 4Selvaggi G, Novello S,Torri V,et al. Epidermal growth factorreceptor overexpression correlates with a poor prognosis in com-pletely resected non-small cell lung cancer [J]. Ann Oncol,2004, 15(l):28-32.
  • 5Chiarugi P, Cirri P. Redox regulation of protein tyrosine phos-phatases during receptor tyrosine kinase signal transduction[JJ.Trends Biochem Sci,2003,28(9) : 509-514.
  • 6Huang SM, Armstrong EA,Harari PM. Modulation of radia-tion response and tumor-induced angiogenesis after epidermalgrowth factor receptor inhibition by ZD1839(Iressa)[J]. CancerRes, 2002, 62(15):4300-4306.
  • 7Lammering G, Molecular predictor and promising target . will EGFRnow become a star in radiotherapy [J]. Radiother Oncol . 2005, 74(2):89-91.
  • 8Zhang N,Erjala K,Kulmala J,et al. Concurrent cetuximab,cis-platin,and radiation for squamous cell carcinaoma of the headand neck in vitro[J]. Radiother 0ncol,2009,92(3) :388-392.
  • 9Bonner JA,Harari PM,Giralt J,et al. Radiotherapy plus cetux-imab for locoregionally advanced head and neck cancer: 5-yearsurvival data from a phase 3 randomised trial, and relation be-tween cetuximab-induced rash and survival [ J]. Lancet Oncol,2010,11(1):21-28.
  • 10彭培建,林忠,廖海,李苏,张力.吉非替尼对鼻咽癌细胞抑制作用及其对EGFR表达影响的探讨[J].中华肿瘤防治杂志,2009,16(13):978-981. 被引量:4

二级参考文献26

  • 1宗井凤,马骏,唐玲珑,刘立志,孙颖,黄莹,林爱华,卢泰祥.鼻咽癌临床分期因素意义的探讨[J].国际肿瘤学杂志,2006,33(1):71-75. 被引量:22
  • 2黄晓东,易俊林,高黎,徐国镇,李素艳,蔡伟明,罗京伟.放疗前贫血对鼻咽癌预后的影响[J].中华放射肿瘤学杂志,2006,15(2):73-76. 被引量:30
  • 3孙折玉,麦海强,谢传淼,赵正军,齐斌,洪明晃,郭翔,莫浩元.鼻咽癌咽旁间隙侵犯对预后的影响[J].中华肿瘤防治杂志,2006,13(10):756-759. 被引量:5
  • 4高黎,易俊林,黄晓东,李素艳,罗京伟,徐国镇.鼻咽癌根治性放疗10年经验总结[J].中华放射肿瘤学杂志,2006,15(4):249-256. 被引量:144
  • 5Au J S, Law C K, Foo W, Lau W H. In-depth evaluation of the AJCC/UICC 1997 staging system of nasopharyngeal carcinoma: Prognostic homogeneity and proposed refinements[J]. Int J Ra diat Oncol Biol Phys, 2003, 56(2) :413-426.
  • 6Yeh S A, Tang Y, Lui C C, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone[J]. Int J Radiat Oncol Biol Phys, 2005, 62(3):672- 679.
  • 7Chua D T, Sham J S, Wei W I, et al. The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma[J].Cancer, 2001, 92(11):2845-2855.
  • 8Cheng S H, Yen K L, Jian J J, et al. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: Impact on future clinical trials[J]. Int J Radiat Oncol Biol Phys, 2001, 50 (3) :717-726.
  • 9Palazzi M, Guzzo M, Tomatis S, et al. Improved outcome of na sopharyngeal carcinoma treated with conventional radiotherapy[J].Int J Radiat Oncol Biol Phys, 2004, 60(5):1451-1458.
  • 10Leung T W, Tung S Y, Sze W K, et al. Treatment results of 1070 patients with nasopharyngeal carcinoma: an analysis of survival and failure patterns[J].Head Neck, 2005, 27(7):555 -565.

共引文献25

同被引文献64

  • 1ESTEVES F P, SCHUSTER D M, HALKAR R K.Gastrointestinal tract malignancies and positron emission tomography: an review [ J ] . Semin Nucl Med, 2006, 36(2): 169-181.
  • 2YU J, LIU F, SUN Z, et al. The enhancement nfradiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism [ J ] . Cancer Biother Radiopharm, 2011, 26(2): 219-227.
  • 3WEIDNER N, SEMPLE J P, WELCH W R, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma [ J ]. N Engl J Med, 199, 324(1): 1-8.
  • 4DAVIS M, LASHEEN W, WALSH D, et al. A phase II dose titration study of thalidomide for cancer-associated [ J ] . J Pain Symptom Manage, 2012, 43(1): 78-86.
  • 5UACH H, RITCHIE D, STEWART A K, et al. Mechanism of action of immunomodulatory drugs (IMiDs) in multiple myeloma [ J ] . Leukemia, 2010, 24(1): 22-32.
  • 6CHEN J, SHAO S, NAKADAL K. Dominant-negative hypoxia inducible factor-1 alpha reduces tumorigenicity of pan creatic cancer cells through the suppression of glucoise metabolism [ J ] . Am J Pathol, 2003, 162(4): 1283-1291.
  • 7YIM S F, LOK I H, CHEUNG L P, et al. Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF [ J ] . Hum Reprod, 2001, 16(3): 492-494.
  • 8ANSIAUX R, BAUDELET C, JORDAN B F, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment [ J ] . Clin Cancer Res, 2005, 11(2Pt1): 743-750.
  • 9Rogers SN, Ahad SA, Murphy AP. A structured review and theme anal- ysis of papers published on quality of lifein head and neck cancer:2000 -2005[ J]. Oral Oncol, 2007,43(9) :843 -868.
  • 10Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma [ J ]. Cancer, 2005,103 ( 1 ) :22 - 31.

引证文献4

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部